TRAK2

Across TCGA pan-cancer cohorts, TRAK2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRAK2 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRAK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, SCLC, and UCEC are the cancer types where TRAK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.195	0.710	.019	18	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
UCEC	DFS	Median	All	0.968	0.622	.007	12	view →
COAD	DFS	Median	IV	0.028	0.496	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRAK2–HNSC (DFS)

Open the HNSC breakdown →